Related references
Note: Only part of the references are listed.Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance
Melanie A. Krook et al.
BRITISH JOURNAL OF CANCER (2021)
Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class
April Weaver et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2021)
Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors
Francesco Facchinetti et al.
CLINICAL CANCER RESEARCH (2020)
INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models
Phillip C. C. Liu et al.
PLOS ONE (2020)
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2020)
Relevance of Half-Life in Drug Design
Dennis A. Smith et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Strategy for Extending Half-life in Drug Design and Its Significance
Hakan Gunaydin et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplified and non-amplified metastatic breast cancer.
F. Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Preliminary results from a phase 1/2 study of INCB054828, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced malignancies
Mansoor Saleh et al.
CANCER RESEARCH (2017)
Volume of Distribution in Drug Design
Dennis A. Smith et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Novel tactics for designing water-soluble molecules in drug discovery
Michael A. Walker
EXPERT OPINION ON DRUG DISCOVERY (2014)
Fibroblast Growth Factor Receptor 2 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Cholangiocarcinoma
Yasuhito Arai et al.
HEPATOLOGY (2014)
The significance of acid/base properties in drug discovery
David T. Manallack et al.
CHEMICAL SOCIETY REVIEWS (2013)
Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives
Maria Vittoria Dieci et al.
CANCER DISCOVERY (2013)
Mitigating Heterocycle Metabolism in Drug Discovery
David J. St Jean et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure-Activity Relationships and Discovery Strategies To Mitigate Drug-Drug Interaction Risks
Suvi T. M. Orr et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors
D. J. Jonker et al.
ANNALS OF ONCOLOGY (2011)
Deep understanding of structure-solubility relationship for a diverse set of organic compounds using matched molecular pairs
Lying Zhang et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2011)
Recent advances and novel strategies in pre-clinical formulation development: An overview
Amit K. Shah et al.
JOURNAL OF CONTROLLED RELEASE (2011)
Improvement in Aqueous Solubility in Small Molecule Drug Discovery Programs by Disruption of Molecular Planarity and Symmetry
Minoru Ishikawa et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
De-regulated FGF receptors as therapeutic targets in cancer
Victoria Knights et al.
PHARMACOLOGY & THERAPEUTICS (2010)
Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
Jonathan Weiss et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Fibroblast growth factor signalling: from development to cancer
Nicholas Turner et al.
NATURE REVIEWS CANCER (2010)
Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success
Frank Lovering et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
The FGF family: biology, pathophysiology and therapy
Andrew Beenken et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival
Kaiko Kunii et al.
CANCER RESEARCH (2008)
Fibroblast growth factor signaling in tumorigenesis
R Grose et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2005)
Cellular signaling by fibroblast growth factor receptors
VP Eswarakumar et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2005)
Preparative LC-MS purification: Improved compound-specific method optimization
KF Blom et al.
JOURNAL OF COMBINATORIAL CHEMISTRY (2004)
Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders
BWG van Rhijn et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2002)
Molecular properties that influence the oral bioavailability of drug candidates
DF Veber et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
The 8p11 myeloproliferative syndrome: A distinct clinical entity caused by constitutive activation of FGFR1
D Macdonald et al.
ACTA HAEMATOLOGICA (2002)
Property-based design: Optimization of drug absorption and pharmacokinetics
H van de Waterbeemd et al.
JOURNAL OF MEDICINAL CHEMISTRY (2001)
Share Paper
